NCT07013123 - Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

August 18, 2029

Study Completion Date

August 18, 2029

Conditions

Severe AsthmaAllergy to House Dust Mites

Interventions

DRUG

Tezepelumab

"Patients will take Tezepelumab for 3 to 6 months (M-3/-6) to control asthma symptoms.~Once asthma symptoms are controlled (D0), patients will take an additionnal of 18 months of Tezepelumab"

DRUG

Acarizax

Once asthma symptoms are controlled (D0), patients will take 18 months of Acarizax.

DRUG

Placebo

Once asthma symptoms are controlled (D0), patients will take 18 months of Placebo.